pd

AskBio’s investigational gene therapy AB-1005 has been granted fast-track designation for Parkinson’s disease by the U.S. Food and Drug Administration (FDA), and innovation passport designation by the regulatory agency in the U.K. These designations are meant to accelerate the development and review process of therapy candidates designed to treat serious conditions and fill unmet clinical … Read more

It’s that time of year again: time for our annual Walk for Parkinson’s. I hate asking people for money, even for such a worthwhile cause as our local Parkinson’s Society here in Ontario, Canada. Since my diagnosis of Parkinson’s disease in 2015, however, I’ve felt the cause is too important to ignore, not just for … Read more

The first three Parkinson’s disease patients who received a low dose of TED-A9, an investigational stem cell-based therapy being developed by S.Biomedics, saw reduced motor symptoms after a year without any reported side effects. The results come from a small Phase 1/2 clinical study (NCT05887466) where 12 adults with a diagnosis of Parkinson’s for five … Read more

Scientists have discovered a new regulator — called NHR-49 — that may shed light and open potential new therapeutic avenues to prevent the formation of toxic protein clumps, a hallmark of aging-related diseases, including Parkinson’s disease. Using embryos of the roundworm Caenorhabditis elegans, they found that NHR-49 is activated in response to stress and elicits … Read more

Anew Medical said it will advance clinical development of its Klotho gene therapy program to prevent or stop the progression of neurodegenerative diseases, including Parkinson’s disease. Initial data suggest that maintaining high levels of the Klotho protein in the body may help people live longer and healthier lives, while individuals with lower levels of the … Read more